Sahin, E. Et Al. 2019. Vulpinic acid, a lichen metabolite, emerges as a potential drug candidate in the therapy of oxidative stress–related diseases, such as atherosclerosis. Human and Experimental Toxicology , vol.38, no.6 , 675-684.

Sahin, E., Dabagoglu Psav, S., Avan, I., Candan, M., ŞAHİNTÜRK, V., & Koparal, A. T., (2019). Vulpinic acid, a lichen metabolite, emerges as a potential drug candidate in the therapy of oxidative stress–related diseases, such as atherosclerosis. Human and Experimental Toxicology , vol.38, no.6, 675-684.

Sahin, E. Et Al. "Vulpinic acid, a lichen metabolite, emerges as a potential drug candidate in the therapy of oxidative stress–related diseases, such as atherosclerosis," Human and Experimental Toxicology , vol.38, no.6, 675-684, 2019

Sahin, E. Et Al. "Vulpinic acid, a lichen metabolite, emerges as a potential drug candidate in the therapy of oxidative stress–related diseases, such as atherosclerosis." Human and Experimental Toxicology , vol.38, no.6, pp.675-684, 2019

Sahin, E. Et Al. (2019) . "Vulpinic acid, a lichen metabolite, emerges as a potential drug candidate in the therapy of oxidative stress–related diseases, such as atherosclerosis." Human and Experimental Toxicology , vol.38, no.6, pp.675-684.

@article{article, author={E. Sahin Et Al. }, title={Vulpinic acid, a lichen metabolite, emerges as a potential drug candidate in the therapy of oxidative stress–related diseases, such as atherosclerosis}, journal={Human and Experimental Toxicology}, year=2019, pages={675-684} }